|
| 36657993 | CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity. | Neurol Neuroimmunol Neuroinflamm | 2023 |
| 37897254 | Susceptibility-based imaging aids accurate distinction of pediatric-onset MS from myelin oligodendrocyte glycoprotein antibody-associated disease. | Mult Scler | 2023 |
| 37828380 | Targeting PGLYRP1 in cancer and autoimmunity. | Nat Immunol | 2023 |
| 37673687 | A 28-Year-Old Woman With Left-Sided Weakness and Atypical MRI Lesions: From the National Multiple Sclerosis Society Case Conference Proceedings. | Neurol Neuroimmunol Neuroinflamm | 2023 |
| 37291385 | Defining blood-induced microglia functions in neurodegeneration through multiomic profiling. | Nat Immunol | 2023 |
| 37185261 | Low protection from breakthrough SARS-CoV-2 infection and mild disease course in ocrelizumab-treated patients with multiple sclerosis after three mRNA vaccine doses. | J Neurol Neurosurg Psychiatry | 2023 |
| 37015826 | Relapsing Encephalomyelitis After COVID-19 Infection and Vaccination: From the National MS Society Case Conference Proceedings. | Neurol Neuroimmunol Neuroinflamm | 2023 |
| 37205595 | A Predictive Autoantibody Signature in Multiple Sclerosis. | medRxiv | 2023 |
| 37463205 | T cell deletional tolerance restricts AQP4 but not MOG CNS autoimmunity. | Proc Natl Acad Sci U S A | 2023 |
| 36873431 | SAkuraBONSAI: Protocol design of a novel, prospective study to explore clinical, imaging, and biomarker outcomes in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder receiving open-label satralizumab. | Front Neurol | 2023 |
| 36608538 | Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators. | Mult Scler Relat Disord | 2023 |
| 36596717 | <i>N2</i> Year in Review. | Neurol Neuroimmunol Neuroinflamm | 2023 |
| 35334278 | Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients. | Mult Scler Relat Disord | 2022 |
| 35397292 | A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial. | Mult Scler Relat Disord | 2022 |
| 36517233 | MOG Antibody-Associated Disease and Thymic Hyperplasia: From the National Multiple Sclerosis Society Case Conference Proceedings. | Neurol Neuroimmunol Neuroinflamm | 2022 |
| 36270950 | Multiple Sclerosis Followed by Neuromyelitis Optica Spectrum Disorder: From the National Multiple Sclerosis Society Case Conference Proceedings. | Neurol Neuroimmunol Neuroinflamm | 2022 |
| 36357190 | Recurrent Optic Neuritis and Perineuritis Followed by an Unexpected Discovery: From the National Multiple Sclerosis Society Case Conference Proceedings. | Neurol Neuroimmunol Neuroinflamm | 2022 |
| 34878197 | Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. | Ann Neurol | 2022 |
| 35030101 | Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function. | JCI Insight | 2022 |
| 35233827 | Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS". | Ann Neurol | 2022 |
| 33971376 | Application of an evidence-based, out-patient treatment strategy for COVID-19: Multidisciplinary medical practice principles to prevent severe disease. | J Neurol Sci | 2021 |
| 33649164 | CNS Autoimmune Responses in BCMA-Deficient Mice Provide Insight for the Failure of Atacicept in MS. | Neurol Neuroimmunol Neuroinflamm | 2021 |
| 33504809 | A CD8<sup>+</sup> NK cell transcriptomic signature associated with clinical outcome in relapsing remitting multiple sclerosis. | Nat Commun | 2021 |
| 33503348 | Antigen Presentation by B Cells in Multiple Sclerosis. | N Engl J Med | 2021 |
| 34671772 | SARS-CoV-2 spike protein induces abnormal inflammatory blood clots neutralized by fibrin immunotherapy. | bioRxiv | 2021 |
| 34580672 | Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity. | medRxiv | 2021 |
| 34571415 | Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis. | Mult Scler Relat Disord | 2021 |
| 34652961 | Lymph node-resident dendritic cells drive T<sub>H</sub>2 cell development involving MARCH1. | Sci Immunol | 2021 |
| 34001659 | Can Systemic Anti-CD20 B Cell-Depleting Antibodies Eliminate Meningeal Follicles in Multiple Sclerosis? | Neurol Neuroimmunol Neuroinflamm | 2021 |
| 34162741 | Encephalitis and Myelitis in a Young Woman: Overlap Syndrome, Thyroiditis, and Occult Tumor From the National Multiple Sclerosis Society Case Conference Proceedings. | Neurol Neuroimmunol Neuroinflamm | 2021 |
| 32532449 | Part I. SARS-CoV-2 triggered 'PANIC' attack in severe COVID-19. | J Neurol Sci | 2020 |
| 32029531 | Intrathecal B-cell activation in LGI1 antibody encephalitis. | Neurol Neuroimmunol Neuroinflamm | 2020 |
| 32081067 | New cases of vasculitis after alemtuzumab. | Mult Scler | 2020 |
| 31772285 | Publisher Correction: B cells in autoimmune and neurodegenerative central nervous system diseases. | Nat Rev Neurosci | 2020 |
| 31848576 | Reply: Neither human nor mouse is hypercalcaemic with 250 nmol/l 25-hydroxyvitamin D. | Brain | 2020 |
| 33434885 | Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 2: From the National Multiple Sclerosis Society Case Conference Proceedings. | Neurol Neuroimmunol Neuroinflamm | 2020 |
| 33406479 | Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1. | Neurol Neuroimmunol Neuroinflamm | 2020 |
| 33154077 | Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. | AJNR Am J Neuroradiol | 2020 |
| 33411674 | Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2. | Neurol Neuroimmunol Neuroinflamm | 2020 |
| 33411672 | Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference Proceedings. | Neurol Neuroimmunol Neuroinflamm | 2020 |
| 33411673 | <i>N2</i> year in review. | Neurol Neuroimmunol Neuroinflamm | 2020 |
| 32859762 | A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. | Proc Natl Acad Sci U S A | 2020 |
| 32661365 | Author Correction: Transcriptional profiling and therapeutic targeting of oxidative stress in neuroinflammation. | Nat Immunol | 2020 |
| 32769201 | Mitigating alemtuzumab-associated autoimmunity in MS: A "whack-a-mole" B-cell depletion strategy. | Neurol Neuroimmunol Neuroinflamm | 2020 |
| 32737072 | Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS. | Neurol Neuroimmunol Neuroinflamm | 2020 |
| 32878998 | Ataxin-1 regulates B cell function and the severity of autoimmune experimental encephalomyelitis. | Proc Natl Acad Sci U S A | 2020 |
| 32929024 | The immune signatures of multiple sclerosis: Lessons from twin studies. | Proc Natl Acad Sci U S A | 2020 |
| 32284594 | Transcriptional profiling and therapeutic targeting of oxidative stress in neuroinflammation. | Nat Immunol | 2020 |
| 32527763 | Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019? | Neurol Neuroimmunol Neuroinflamm | 2020 |
| 32184341 | Glatiramer acetate immune modulates B-cell antigen presentation in treatment of MS. | Neurol Neuroimmunol Neuroinflamm | 2020 |